Val
—
Gro
—
Qua
—
Mom
—
Sta
—
Cap—
P/S5.61
P/E—
Fwd P/E17.74
PEG1.21
52W— – —
RSI—
Target$248.6 (+16.0%)
Beta0.78
Div1.12%
Loading chart…
RSI (14)
Loading patterns…
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
52-Week Range
52W Low
—
52W High
Position in Range
—
RSI (14)
0 · Oversold
RSI 61
Overbought · 100
Signal
Neutral
EMA Price Levels
Volume Analysis
Momentum Dashboard
Trend Strength
Detected Patterns
3Bullish
3Bearish
0Neutral
▲ Double Bottom — Two lows ~$182.46 — bullish reversal confirmed
▲ Inv. Head & Shoulders — Inv. H&S neckline ~$205.87 broken — major bullish reversal
▲ Bull Flag — Breakout after +9% pole — bullish continuation
▼ Bear Flag — Breakdown after -9% pole — bearish continuation
▼ Bear Flag — Breakdown after -10% pole — bearish continuation
▼ Bear Flag — Breakdown after -10% pole — bearish continuation
View overlays on the price chart via Chart tab → Pattern Overlays.
EPS — History & Forecast
Estimate
Beat
Miss
Forecast
Loading…
Revenue — History & Forecast
Revenue
Forecast
Loading…
EPS Beat Rate
100%
8/8 quarters
Wall Street Consensus
BUY
BuyHoldSell
Price Target Range
$248.6
+16.0% upside
Low $180
—
High $325
Consensus
Current price
Wall Street Analyst Ratings
| Firm | Rating | Change | Action | Date |
|---|---|---|---|---|
| Mizuho | Outperform | — | ↔ Maintain | 2026-07-15 |
| Citigroup | Neutral | Buy → Neutral | ▼ Downgrade | 2026-07-13 |
| Jefferies | Hold | — | ↔ Maintain | 2026-07-10 |
| RBC Capital | Outperform | — | ↔ Maintain | 2026-07-08 |
| Wells Fargo | Equal-Weight | — | ↔ Maintain | 2026-07-08 |
| Keybanc | Overweight | — | ↔ Maintain | 2026-06-22 |
| Morgan Stanley | Equal-Weight | Overweight → Equal-Weight | ▼ Downgrade | 2026-06-17 |
| Piper Sandler | Neutral | — | ↔ Maintain | 2026-01-30 |
| Stifel | Hold | — | ↔ Maintain | 2026-01-30 |
| Baird | Neutral | Outperform → Neutral | ▼ Downgrade | 2025-12-16 |
Mizuho
2026-07-15
Outperform
↔ Maintain
Citigroup
2026-07-13
Neutral
(from Buy)
▼ Downgrade
Jefferies
2026-07-10
Hold
↔ Maintain
RBC Capital
2026-07-08
Outperform
↔ Maintain
Wells Fargo
2026-07-08
Equal-Weight
↔ Maintain
Keybanc
2026-06-22
Overweight
↔ Maintain
Morgan Stanley
2026-06-17
Equal-Weight
(from Overweight)
▼ Downgrade
Piper Sandler
2026-01-30
Neutral
↔ Maintain
Stifel
2026-01-30
Hold
↔ Maintain
Baird
2025-12-16
Neutral
(from Outperform)
▼ Downgrade
Profitability
Gross Margin
62.18%TTM
Op. Margin
35.33%TTM
ROE
25.25%TTM
Rev. Growth
10.80%YoY
Free Cash Flow
1.45BTTM
FCF Yield
—TTM
Balance Sheet
Debt / Equity
12.99MRQ
Current Ratio
3.01MRQ
Cash
1.66BMRQ
Total Debt
843.17MMRQ
Net Debt
—MRQ
Income
Div. Yield
1.12%TTM
Annual Rate
2.40Fwd
Payout Ratio
22.47%TTM
Dividend History
Payout Ratio (TTM): 22.47%
| Date | Amount / Share | Yield at Payment |
|---|---|---|
| 2026-05-14 | $0.6000 | 0.30% |
| 2026-02-12 | $0.6000 | 0.24% |
| 2025-11-13 | $0.6000 | 0.24% |
| 2025-08-14 | $0.6000 | 0.21% |
| 2025-05-08 | $0.5300 | 0.22% |
| 2025-02-13 | $0.5300 | 0.22% |
| 2024-11-07 | $0.5300 | 0.22% |
| 2024-08-15 | $0.5300 | 0.24% |
| 2024-05-08 | $0.4800 | 0.23% |
| 2024-02-07 | $0.4800 | 0.26% |
| 2023-11-08 | $0.4800 | 0.33% |
| 2023-08-16 | $0.4800 | 0.28% |
| 2023-05-10 | $0.4400 | 0.19% |
| 2023-02-08 | $0.4400 | 0.20% |
| 2022-11-09 | $0.4400 | 0.21% |
| 2022-08-17 | $0.4400 | 0.19% |
| 2022-05-11 | $0.4200 | 0.23% |
| 2022-02-09 | $0.4200 | 0.18% |
| 2021-11-09 | $0.4200 | 0.17% |
| 2021-08-18 | $0.4200 | 0.16% |
| 2021-05-12 | $0.3900 | 0.21% |
| 2021-02-10 | $0.3900 | 0.20% |
| 2020-11-10 | $0.3900 | 0.19% |
| 2020-08-19 | $0.3900 | 0.22% |
| 2020-05-13 | $0.3900 | 0.25% |
| 2020-02-12 | $0.3900 | 0.24% |
| 2019-11-06 | $0.3900 | 0.29% |
| 2019-08-14 | $0.3900 | 0.32% |
| 2019-05-08 | $0.3700 | 0.35% |
| 2019-02-06 | $0.3700 | 0.41% |
| 2018-11-07 | $0.3700 | 0.37% |
| 2018-08-15 | $0.3700 | 0.37% |
| 2018-05-09 | $0.3500 | 0.39% |
| 2018-02-07 | $0.3500 | 0.41% |
| 2017-11-08 | $0.3500 | 0.46% |
| 2017-08-15 | $0.3500 | 0.53% |
| 2017-05-09 | $0.3300 | 0.54% |
| 2017-02-07 | $0.3300 | 0.53% |
| 2016-11-08 | $0.3300 | 0.64% |
| 2016-08-16 | $0.3300 | 0.53% |
How RMD Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
| Quarter | Revenue | Rev YoY | Gross Profit | Op. Income | Net Income | Net YoY | Gross % | Op % | Net % |
|---|
Full Key Statistics
Valuation
| Market Cap | 31.08B |
| Enterprise Value | 30.27B |
| Trailing P/E | 20.68 |
| Forward P/E | 17.74 |
| PEG Ratio (5yr) | 1.21 |
| Price/Sales (ttm) | 5.61 |
| Price/Book (mrq) | 4.79 |
| EV/Revenue | 5.47 |
| EV/EBITDA | 14.28 |
Share Statistics
| Avg Vol (3m) | 1.55M |
| Shares Outstanding | 145.06M |
| Float | 144.16M |
| % Held by Insiders | 0.50% |
| % Held by Institutions | 69.91% |
| Short Ratio | 7.77 |
| Short % of Float | 10.76% |
Profitability
| Gross Margin | 62.18% |
| Operating Margin (ttm) | 35.33% |
| Profit Margin | 27.44% |
| Return on Assets (ttm) | 14.71% |
| Return on Equity (ttm) | 25.25% |
Income Statement
| Revenue (ttm) | 5.54B |
| Revenue Growth (yoy) | 10.80% |
| Gross Profit (ttm) | 3.44B |
| EBITDA | 2.12B |
| Net Income (ttm) | 1.52B |
| Diluted EPS (ttm) | 10.36 |
| EPS Growth (yoy) | 10.50% |
Balance Sheet
| Total Cash (mrq) | 1.66B |
| Total Debt (mrq) | 843.17M |
| Debt / Equity (mrq) | 12.99 |
| Current Ratio (mrq) | 3.01 |
| Book Value / Share | 44.76 |
| Operating CF (ttm) | 1.89B |
| Free Cash Flow (ttm) | 1.45B |
Trading & Dividends
| Beta (5Y) | 0.78 |
| 50-Day MA | 199.07 |
| 200-Day MA | 232.64 |
| Fwd Dividend Yield | 115.00% |
| Payout Ratio | 22.47% |
Ownership Breakdown
Institutional 69.91%
Insider 0.50%
Public 29.6%
Short Interest
10.76% of float
High
Institutional 13F Holdings
Famous investors who disclosed a position in RMD in their latest SEC 13F filing.
Loading…
Insider Transactions
| Date | Insider | Role | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-08 | FARRELL MICHAEL J | Chief Executive Officer | Sale at price 193.96 per share. | 4,991 | $968,064 |
| 2026-06-08 | FARRELL MICHAEL J | Chief Executive Officer | Conversion of Exercise of derivative security at price 146.34 per share. | 4,991 | $730,383 |
| 2026-05-07 | FARRELL MICHAEL J | Chief Executive Officer | Sale at price 207.82 per share. | 4,991 | $1,037,233 |
| 2026-05-07 | FARRELL MICHAEL J | Chief Executive Officer | Conversion of Exercise of derivative security at price 146.34 per share. | 4,991 | $730,383 |
| 2026-04-07 | FARRELL MICHAEL J | Chief Executive Officer | Sale at price 225.50 per share. | 4,991 | $1,125,486 |
| 2026-04-07 | FARRELL MICHAEL J | Chief Executive Officer | Conversion of Exercise of derivative security at price 146.34 per share. | 4,991 | $730,383 |
| 2026-04-01 | SANDERCOCK BRETT | Chief Financial Officer | Sale at price 224.31 per share. | 1,000 | $224,310 |
| 2026-04-01 | FARRELL PETER CRAIG | Director | Sale at price 225.00 per share. | 2,000 | $450,000 |
| 2026-03-09 | FARRELL MICHAEL J | Chief Executive Officer | Sale at price 251.03 per share. | 4,991 | $1,252,902 |
| 2026-03-09 | FARRELL MICHAEL J | Chief Executive Officer | Conversion of Exercise of derivative security at price 146.34 per share. | 4,991 | $730,383 |
| 2026-03-04 | FARRELL PETER CRAIG | Director | Sale at price 260.22 per share. | 2,000 | $520,440 |
| 2026-03-02 | SANDERCOCK BRETT | Chief Financial Officer | Sale at price 254.30 per share. | 1,000 | $254,300 |
| 2026-02-09 | FARRELL MICHAEL J | Chief Executive Officer | Sale at price 273.78 per share. | 4,991 | $1,366,436 |
| 2026-02-09 | FARRELL MICHAEL J | Chief Executive Officer | Conversion of Exercise of derivative security at price 146.34 per share. | 4,991 | $730,383 |
| 2026-02-04 | FARRELL PETER CRAIG | Director | Sale at price 251.31 per share. | 2,000 | $502,620 |
| 2026-02-04 | RIDER MICHAEL J | General Counsel | Sale at price 260.00 per share. | 50 | $13,000 |
| 2026-02-02 | SANDERCOCK BRETT | Chief Financial Officer | Sale at price 257.03 per share. | 1,000 | $257,030 |
| 2026-01-07 | FARRELL PETER CRAIG | Director | Sale at price 248.83 per share. | 2,000 | $497,660 |
| 2026-01-07 | FARRELL MICHAEL J | Chief Executive Officer | Sale at price 248.46 per share. | 4,991 | $1,240,065 |
| 2026-01-07 | FARRELL MICHAEL J | Chief Executive Officer | Conversion of Exercise of derivative security at price 146.34 per share. | 4,991 | $730,383 |
| 2026-01-02 | SANDERCOCK BRETT | Chief Financial Officer | Sale at price 241.75 per share. | 1,000 | $241,750 |
| 2026-01-02 | RIDER MICHAEL J | Officer | Sale at price 241.75 per share. | 50 | $12,088 |
| 2025-12-08 | FARRELL MICHAEL J | Chief Executive Officer | Sale at price 251.41 per share. | 4,991 | $1,254,796 |
| 2025-12-08 | FARRELL MICHAEL J | Chief Executive Officer | Conversion of Exercise of derivative security at price 146.34 per share. | 4,991 | $730,383 |
| 2025-12-03 | FARRELL PETER CRAIG | Director | Sale at price 251.47 per share. | 2,000 | $502,940 |
FARRELL MICHAEL J
Chief Executive Officer
Sale at price 193.96 per share.
2026-06-08
4,991 sh
$968,064
FARRELL MICHAEL J
Chief Executive Officer
Conversion of Exercise of derivative security at price 146.34 per share.
2026-06-08
4,991 sh
$730,383
FARRELL MICHAEL J
Chief Executive Officer
Sale at price 207.82 per share.
2026-05-07
4,991 sh
$1,037,233
FARRELL MICHAEL J
Chief Executive Officer
Conversion of Exercise of derivative security at price 146.34 per share.
2026-05-07
4,991 sh
$730,383
FARRELL MICHAEL J
Chief Executive Officer
Sale at price 225.50 per share.
2026-04-07
4,991 sh
$1,125,486
FARRELL MICHAEL J
Chief Executive Officer
Conversion of Exercise of derivative security at price 146.34 per share.
2026-04-07
4,991 sh
$730,383
SANDERCOCK BRETT
Chief Financial Officer
Sale at price 224.31 per share.
2026-04-01
1,000 sh
$224,310
FARRELL PETER CRAIG
Director
Sale at price 225.00 per share.
2026-04-01
2,000 sh
$450,000
FARRELL MICHAEL J
Chief Executive Officer
Sale at price 251.03 per share.
2026-03-09
4,991 sh
$1,252,902
FARRELL MICHAEL J
Chief Executive Officer
Conversion of Exercise of derivative security at price 146.34 per share.
2026-03-09
4,991 sh
$730,383
FARRELL PETER CRAIG
Director
Sale at price 260.22 per share.
2026-03-04
2,000 sh
$520,440
SANDERCOCK BRETT
Chief Financial Officer
Sale at price 254.30 per share.
2026-03-02
1,000 sh
$254,300
FARRELL MICHAEL J
Chief Executive Officer
Sale at price 273.78 per share.
2026-02-09
4,991 sh
$1,366,436
FARRELL MICHAEL J
Chief Executive Officer
Conversion of Exercise of derivative security at price 146.34 per share.
2026-02-09
4,991 sh
$730,383
FARRELL PETER CRAIG
Director
Sale at price 251.31 per share.
2026-02-04
2,000 sh
$502,620
RIDER MICHAEL J
General Counsel
Sale at price 260.00 per share.
2026-02-04
50 sh
$13,000
SANDERCOCK BRETT
Chief Financial Officer
Sale at price 257.03 per share.
2026-02-02
1,000 sh
$257,030
FARRELL PETER CRAIG
Director
Sale at price 248.83 per share.
2026-01-07
2,000 sh
$497,660
FARRELL MICHAEL J
Chief Executive Officer
Sale at price 248.46 per share.
2026-01-07
4,991 sh
$1,240,065
FARRELL MICHAEL J
Chief Executive Officer
Conversion of Exercise of derivative security at price 146.34 per share.
2026-01-07
4,991 sh
$730,383
SANDERCOCK BRETT
Chief Financial Officer
Sale at price 241.75 per share.
2026-01-02
1,000 sh
$241,750
RIDER MICHAEL J
Officer
Sale at price 241.75 per share.
2026-01-02
50 sh
$12,088
FARRELL MICHAEL J
Chief Executive Officer
Sale at price 251.41 per share.
2025-12-08
4,991 sh
$1,254,796
FARRELL MICHAEL J
Chief Executive Officer
Conversion of Exercise of derivative security at price 146.34 per share.
2025-12-08
4,991 sh
$730,383
FARRELL PETER CRAIG
Director
Sale at price 251.47 per share.
2025-12-03
2,000 sh
$502,940